Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma
PLOS One · 04.03.2026 · 21 (3) · e0328666
DOI: 10.1371/journal.pone.0328666 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.03.2026. Verfasst von Tong-Yoon Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department Of Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Lymphoma, B-Cell. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Low-grade B-cell lymphomas (LGBCLs) account for approximately 40% of non-Hodgkin lymphomas with low progression. LGBCL is divided into subgroups, which share common complications. Analyzing prognostic factors and mortality causes could improve patient survival; however, currently available models present limitations in discriminating the cause of death. Therefore, this study aimed to compare the prognostic factors and causes of death, such as secondary malignancies (SMs), aggressive histologic transformation (HT), and infectious complications, including coronavirus disease 2019 (COVID-19), in LGBCLs using a competing risk analysis.
Methods
This retrospective analysis included 1,047 adults with LGBCLs (follicular lymphoma, 689; marginal zone lymphoma, 312; mantle cell lymphoma [MCL], 46) diagnosed between January 2011 and December 2022 across seven centers. Competing risk models were employed to estimate cumulative incidence rates of lymphoma progression-related and non-lymphoma-related mortality.
Results
Patients with SMs (3.8%) exhibited poorer overall survival than those without SMs, whereas HT and COVID-19 status did not impact survival outcomes in multivariate analysis. Analysis revealed an association of SMs, age > 60 years, male sex, pleural effusion, and elevated lactate dehydrogenase levels with worse non-lymphoma-related mortality. Moreover, age > 60 years, MCL, nodal MZL, and anemia were linked to poorer outcomes for lymphoma progression-related death.
Conclusions
The management of non-lymphoma-related risk factors, such as through early SM detection, is crucial for improving the survival of patients with LGBCLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department Of Hematology, Yeoido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department Of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department Of Oncology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department Of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department Of Hematology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department Of Oncology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Tong-Yoon Kim, Youngwoo Jeon
Zitieren
APA
Kim, T. Y., Min, G. J., Cho, S. G., Kim, S., Lee, J. H., Kim, B. S., Jeoung, J. W., Won, H. S., & Jeon, Y. (2026). Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma. PLOS One, 21(3), e0328666. https://doi.org/10.1371/journal.pone.0328666
Vancouver
Kim TY, Min GJ, Cho SG, Kim S, Lee JH, Kim BS, et al. Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma. PLOS One. 2026;21(3):e0328666. doi:10.1371/journal.pone.0328666
BibTeX
@article{Kim2026,
author = {Kim, Tong-Yoon and Min, Gi-June and Cho, Seok-Goo and Kim, Seoree and Lee, Jong Hyuk and Kim, Byung-Su and Jeoung, Joon Won and Won, Hye Sung and Jeon, Youngwoo},
title = {Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0328666},
doi = {10.1371/journal.pone.0328666}
}
EUVIMED